Physicians' Academy for Cardiovascular Education

hsCRP reduced by GLP-1RA in patients with T2DM

News - Oct. 1, 2021

Semaglutide reduces hsCRP levels across different treatment settings: post hoc analyses of SUSTAIN and PIONEER trials

Presented at the EASD 2021 by: Ofri Mosenzon, MD – Jerusalem, Israel

Introduction and methods

It has been reported that high-sensitivity C-reactive protein (hsCRP) is elevated in patients with T2DM. There is limited evidence on the effects of GLP-1RAs on hsCRP.

This exploratory analysis examined the effect of semaglutide (subcutaneous and oral) vs. comparators on hsCRP levels in patients with T2DM.

Data on hsCRP in four semaglutide trials were used: SUSTAIN 3 (once-weekly SC semaglutide vs. once-weekly exenatide), PIONEER 1 (once-daily oral semaglutide vs. placebo), PIONEER 2 (once-daily oral semaglutide vs. once-daily empagliflozin) and PIONEER 5 (one-daily oral semaglutide vs placebo). Baseline characteristics of patients in PIONEER 5 were different from those of patients in the other trials.

Main results

Conclusion

This analysis showed that semaglutide (subcutaneous and oral) reduced hsCRP when compared to comparators in patients with diabetes, which may partially be explained by reductions in HbA1c and body weight.

More trials, such as the SOUL and SELECT, will provide more insights in the effect of semaglutide on inflammation and CV effect in patients with T2DM and obesity. Currently, renal outcomes with semaglutide are studied in patients with T2DM and CKD in the FLOW trial, said dr. Mosenzon.

Share this page with your colleagues and friends: